The effect of intravenous bumetanide in man with normal and low renal function.
Bumetanide was administered intravenously to four groups of patients with varying levels of glomerular filtration rate (average 10 to 108 ml/min/1.73 m2 B.S.A.). The dose of bumetanide was either 0.25, 0.5, 1.0, or 2.0 mg administered by intravenous "push." The intravenous administration produced a prompt and marked increase in sodium, chloride, and calcium excretion. The effect was brief, lasting 30 to 60 minutes, but persisted to some extent with the 2.0 mg dose beyond 120 minutes. There was no effect on phosphate excretion or on the parameters of net acid excretion.
D000293:Adolescent; D000328:Adult; D001639:Bicarbonates / Q000378:metabolism; D002034:Bumetanide / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D002712:Chlorides / Q000378:metabolism; D004232:Diuretics / Q000494:pharmacology*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007263:Infusions, Parenteral; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism; D012964:Sodium / Q000378:metabolism
D001639:Bicarbonates; D002712:Chlorides; D004232:Diuretics; D010710:Phosphates; D002034:Bumetanide; D012964:Sodium; D002118:Calcium